Herantis Pharma
Business Services · Finland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bertel Jungin Aukio 1, Espoo, Uusimaa, 0...Phone Number
+358 92221195Website
www.herantis.comRevenue
-Industry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Herantis Pharma
Herantis Pharma specializes in developing innovative, disease-modifying therapies aimed at halting or reversing the progression of neurodegenerative diseases. The company addresses significant unmet medical needs through its advanced research and clinical trials. It focuses on bringing transformative solutions to patients suffering from such conditions. Herantis Pharma partners with various stakeholders, including investors and scientific communities, to enhance their therapeutic offerings.Explore more
Herantis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Herantis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Herantis Pharma is spiking on competitors!
Check if Herantis Pharma has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Herantis Pharma has new funding data
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Herantis Pharma recently announced quarterly report
Herantis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Herantis Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Herantis Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Herantis Pharma
Recommended Actions
Find VP level buyers at Herantis Pharma
Find 2 more new buyers
Company Profile Activity
Activity Insights
Herantis Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Herantis Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Herantis Pharma.
Herantis Pharma Tech Stack
A closer look at the technologies used by Herantis Pharma
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
Herantis Pharma has reported that its Phase 1b trial showed no treatment-emergent adverse events on the systemic level, no serious adverse events, no dose-limiting toxicities, and did not reach the maximum tolerated dose.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Herantis Pharma has reported that its Phase 1b trial demonstrated HER-096 presence in cerebrospinal fluid of Parkinson's patients at approximately 100 nanograms per mL with the 200 mg dose and approximately 150 nanograms per mL with the 300 mg dose.
Medical Research, Pharmaceuticals
Earnings
reported long-term debt increased from EUR 2.1 million in 2024 to EUR 3.4 million in 2025. The increase is due to research funding received from Michael J. Fox Foundation and Parkinson's UK.
Research & Development, Finance, Financing & Debt
Earnings
Earnings, Accounting, Financial Reporting, Finance
Herantis Pharma News & Media
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
Espoo, Finland, 2 June 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today provides an update on preparations for the Phase 2a proof-of-concept efficacy study of HER-096, its lead candidate for the treatment of Parkinson's disease, ahead of its webcast being hosted later today at 13.00 EEST (12:00 CEST).Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases
Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri Huttunen, will be delivering an oral presentation at the 20th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026), held in Denmark from 17-21 March, on data from Herantis’s Phase 1b trial of HER-096 in people livHerantis Pharma releases 2H and FY 2025 report today
Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Herantis Pharma
Sign Up For FreeTo access detailed company insights
Herantis Pharma specializes in developing innovative, disease-modifying therapies aimed at halting or reversing the progression of neurodegenerative diseases. The company addresses significant unmet medical needs through its advanced research and clinical trials. It focuses on bringing transformative solutions to patients suffering from such condit... Read More
